high-density three-dimensional electroanatomic mapping system ensite precision Search Results


high-density threedimensional electroanatomic mapping system ensite precision  (Abbott Laboratories)
90
Abbott Laboratories high-density threedimensional electroanatomic mapping system ensite precision
High Density Threedimensional Electroanatomic Mapping System Ensite Precision, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/high-density threedimensional electroanatomic mapping system ensite precision/product/Abbott Laboratories
Average 90 stars, based on 1 article reviews
high-density threedimensional electroanatomic mapping system ensite precision - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
high-density three-dimensional electroanatomic map  (Biosense Webster)
90
Biosense Webster high-density three-dimensional electroanatomic map
High Density Three Dimensional Electroanatomic Map, supplied by Biosense Webster, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/high-density three-dimensional electroanatomic map/product/Biosense Webster
Average 90 stars, based on 1 article reviews
high-density three-dimensional electroanatomic map - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
high-density threedimensional electroanatomic mapping system rhythmia  (Boston Scientific Corporation)
90
Boston Scientific Corporation high-density threedimensional electroanatomic mapping system rhythmia
High Density Threedimensional Electroanatomic Mapping System Rhythmia, supplied by Boston Scientific Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/high-density threedimensional electroanatomic mapping system rhythmia/product/Boston Scientific Corporation
Average 90 stars, based on 1 article reviews
high-density threedimensional electroanatomic mapping system rhythmia - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
high-density threedimensional electroanatomic mapping system carto 3  (Biosense Webster)
90
Biosense Webster high-density threedimensional electroanatomic mapping system carto 3
High Density Threedimensional Electroanatomic Mapping System Carto 3, supplied by Biosense Webster, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/high-density threedimensional electroanatomic mapping system carto 3/product/Biosense Webster
Average 90 stars, based on 1 article reviews
high-density threedimensional electroanatomic mapping system carto 3 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
electroanatomic mapping carto3  (Biosense Webster)
90
Biosense Webster electroanatomic mapping carto3
Electroanatomic Mapping Carto3, supplied by Biosense Webster, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/electroanatomic mapping carto3/product/Biosense Webster
Average 90 stars, based on 1 article reviews
electroanatomic mapping carto3 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
high-density three-dimensional electroanatomic mapping  (Boston Scientific Corporation)
90
Boston Scientific Corporation high-density three-dimensional electroanatomic mapping
Experimental protocol and delivery technique. (A) Myocardial infarction was induced by 90 min balloon occlusion of the proximal anterior descending branch of the left coronary artery followed by 8 weeks of reperfusion. Cardiac function and scar size were examined by magnetic resonance imaging. Arrhythmia inducibility was probed by programmed electrical stimulation at the left ventricular scar border. If no sustained arrhythmia was induced, programmed electrical stimulation was repeated at the right ventricular apex. High-density three-dimensional <t>electroanatomic</t> mapping was then performed (Rhythmia®, Boston Scientific). Inducible animals were randomly assigned to receive focal injections of either 7.5 mg of CDCEXO in 2 mL of IMDM or 2 mL of IMDM alone. Injections were performed in areas where late potentials were identified using electroanatomical mapping and confirmed by point-by-point mapping (NOGA®, Biosense Webster). Magnetic resonance imaging, electroanatomical mapping, and programmed electrical stimulation were repeated 2 weeks later. Animals were then euthanized, and the heart was removed for histologic and proteomic analysis. (B: Left) High-definition electroanatomical mapping image of the arrhythmogenic substrate with an identified late potential. (Centre) Schematic representation of delivery technique using intracardiac injection catheter (Myostar®, Biosense Webster). (Right) Representative NOGA® map with injection sites (black dots). (C) Animals injected with vehicle alone showed diminished contractile function (CDCEXO 3.11 ± 3.75% vs. control −4.7 ± 4.04%, P = 0.0006). (D) Cardiac output increased in CDCEXO pigs (CDCEXO 278.1 ± 414 mL/min vs. control −586 ± 605 mL/min, P = 0.0027). (E) Deleterious changes in end-systolic volumes (CDCEXO −1.4 ± 3.3 mL vs. control 8 ± 8.2 mL, P = 0.005) were observed in control but not in CDCEXO pigs. A two-tailed t-test was used to compare the changes between groups.
High Density Three Dimensional Electroanatomic Mapping, supplied by Boston Scientific Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/high-density three-dimensional electroanatomic mapping/product/Boston Scientific Corporation
Average 90 stars, based on 1 article reviews
high-density three-dimensional electroanatomic mapping - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
high-density mapping catheter pentaray  (Biosense Webster)
90
Biosense Webster high-density mapping catheter pentaray
Experimental protocol and delivery technique. (A) Myocardial infarction was induced by 90 min balloon occlusion of the proximal anterior descending branch of the left coronary artery followed by 8 weeks of reperfusion. Cardiac function and scar size were examined by magnetic resonance imaging. Arrhythmia inducibility was probed by programmed electrical stimulation at the left ventricular scar border. If no sustained arrhythmia was induced, programmed electrical stimulation was repeated at the right ventricular apex. High-density three-dimensional <t>electroanatomic</t> mapping was then performed (Rhythmia®, Boston Scientific). Inducible animals were randomly assigned to receive focal injections of either 7.5 mg of CDCEXO in 2 mL of IMDM or 2 mL of IMDM alone. Injections were performed in areas where late potentials were identified using electroanatomical mapping and confirmed by point-by-point mapping (NOGA®, Biosense Webster). Magnetic resonance imaging, electroanatomical mapping, and programmed electrical stimulation were repeated 2 weeks later. Animals were then euthanized, and the heart was removed for histologic and proteomic analysis. (B: Left) High-definition electroanatomical mapping image of the arrhythmogenic substrate with an identified late potential. (Centre) Schematic representation of delivery technique using intracardiac injection catheter (Myostar®, Biosense Webster). (Right) Representative NOGA® map with injection sites (black dots). (C) Animals injected with vehicle alone showed diminished contractile function (CDCEXO 3.11 ± 3.75% vs. control −4.7 ± 4.04%, P = 0.0006). (D) Cardiac output increased in CDCEXO pigs (CDCEXO 278.1 ± 414 mL/min vs. control −586 ± 605 mL/min, P = 0.0027). (E) Deleterious changes in end-systolic volumes (CDCEXO −1.4 ± 3.3 mL vs. control 8 ± 8.2 mL, P = 0.005) were observed in control but not in CDCEXO pigs. A two-tailed t-test was used to compare the changes between groups.
High Density Mapping Catheter Pentaray, supplied by Biosense Webster, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/high-density mapping catheter pentaray/product/Biosense Webster
Average 90 stars, based on 1 article reviews
high-density mapping catheter pentaray - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ensite x  (Abbott Laboratories)
90
Abbott Laboratories ensite x
Experimental protocol and delivery technique. (A) Myocardial infarction was induced by 90 min balloon occlusion of the proximal anterior descending branch of the left coronary artery followed by 8 weeks of reperfusion. Cardiac function and scar size were examined by magnetic resonance imaging. Arrhythmia inducibility was probed by programmed electrical stimulation at the left ventricular scar border. If no sustained arrhythmia was induced, programmed electrical stimulation was repeated at the right ventricular apex. High-density three-dimensional <t>electroanatomic</t> mapping was then performed (Rhythmia®, Boston Scientific). Inducible animals were randomly assigned to receive focal injections of either 7.5 mg of CDCEXO in 2 mL of IMDM or 2 mL of IMDM alone. Injections were performed in areas where late potentials were identified using electroanatomical mapping and confirmed by point-by-point mapping (NOGA®, Biosense Webster). Magnetic resonance imaging, electroanatomical mapping, and programmed electrical stimulation were repeated 2 weeks later. Animals were then euthanized, and the heart was removed for histologic and proteomic analysis. (B: Left) High-definition electroanatomical mapping image of the arrhythmogenic substrate with an identified late potential. (Centre) Schematic representation of delivery technique using intracardiac injection catheter (Myostar®, Biosense Webster). (Right) Representative NOGA® map with injection sites (black dots). (C) Animals injected with vehicle alone showed diminished contractile function (CDCEXO 3.11 ± 3.75% vs. control −4.7 ± 4.04%, P = 0.0006). (D) Cardiac output increased in CDCEXO pigs (CDCEXO 278.1 ± 414 mL/min vs. control −586 ± 605 mL/min, P = 0.0027). (E) Deleterious changes in end-systolic volumes (CDCEXO −1.4 ± 3.3 mL vs. control 8 ± 8.2 mL, P = 0.005) were observed in control but not in CDCEXO pigs. A two-tailed t-test was used to compare the changes between groups.
Ensite X, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ensite x/product/Abbott Laboratories
Average 90 stars, based on 1 article reviews
ensite x - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ensite precision  (Abbott Laboratories)
90
Abbott Laboratories ensite precision
Experimental protocol and delivery technique. (A) Myocardial infarction was induced by 90 min balloon occlusion of the proximal anterior descending branch of the left coronary artery followed by 8 weeks of reperfusion. Cardiac function and scar size were examined by magnetic resonance imaging. Arrhythmia inducibility was probed by programmed electrical stimulation at the left ventricular scar border. If no sustained arrhythmia was induced, programmed electrical stimulation was repeated at the right ventricular apex. High-density three-dimensional <t>electroanatomic</t> mapping was then performed (Rhythmia®, Boston Scientific). Inducible animals were randomly assigned to receive focal injections of either 7.5 mg of CDCEXO in 2 mL of IMDM or 2 mL of IMDM alone. Injections were performed in areas where late potentials were identified using electroanatomical mapping and confirmed by point-by-point mapping (NOGA®, Biosense Webster). Magnetic resonance imaging, electroanatomical mapping, and programmed electrical stimulation were repeated 2 weeks later. Animals were then euthanized, and the heart was removed for histologic and proteomic analysis. (B: Left) High-definition electroanatomical mapping image of the arrhythmogenic substrate with an identified late potential. (Centre) Schematic representation of delivery technique using intracardiac injection catheter (Myostar®, Biosense Webster). (Right) Representative NOGA® map with injection sites (black dots). (C) Animals injected with vehicle alone showed diminished contractile function (CDCEXO 3.11 ± 3.75% vs. control −4.7 ± 4.04%, P = 0.0006). (D) Cardiac output increased in CDCEXO pigs (CDCEXO 278.1 ± 414 mL/min vs. control −586 ± 605 mL/min, P = 0.0027). (E) Deleterious changes in end-systolic volumes (CDCEXO −1.4 ± 3.3 mL vs. control 8 ± 8.2 mL, P = 0.005) were observed in control but not in CDCEXO pigs. A two-tailed t-test was used to compare the changes between groups.
Ensite Precision, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ensite precision/product/Abbott Laboratories
Average 90 stars, based on 1 article reviews
ensite precision - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ensite navx  (Abbott Laboratories)
90
Abbott Laboratories ensite navx
Experimental protocol and delivery technique. (A) Myocardial infarction was induced by 90 min balloon occlusion of the proximal anterior descending branch of the left coronary artery followed by 8 weeks of reperfusion. Cardiac function and scar size were examined by magnetic resonance imaging. Arrhythmia inducibility was probed by programmed electrical stimulation at the left ventricular scar border. If no sustained arrhythmia was induced, programmed electrical stimulation was repeated at the right ventricular apex. High-density three-dimensional <t>electroanatomic</t> mapping was then performed (Rhythmia®, Boston Scientific). Inducible animals were randomly assigned to receive focal injections of either 7.5 mg of CDCEXO in 2 mL of IMDM or 2 mL of IMDM alone. Injections were performed in areas where late potentials were identified using electroanatomical mapping and confirmed by point-by-point mapping (NOGA®, Biosense Webster). Magnetic resonance imaging, electroanatomical mapping, and programmed electrical stimulation were repeated 2 weeks later. Animals were then euthanized, and the heart was removed for histologic and proteomic analysis. (B: Left) High-definition electroanatomical mapping image of the arrhythmogenic substrate with an identified late potential. (Centre) Schematic representation of delivery technique using intracardiac injection catheter (Myostar®, Biosense Webster). (Right) Representative NOGA® map with injection sites (black dots). (C) Animals injected with vehicle alone showed diminished contractile function (CDCEXO 3.11 ± 3.75% vs. control −4.7 ± 4.04%, P = 0.0006). (D) Cardiac output increased in CDCEXO pigs (CDCEXO 278.1 ± 414 mL/min vs. control −586 ± 605 mL/min, P = 0.0027). (E) Deleterious changes in end-systolic volumes (CDCEXO −1.4 ± 3.3 mL vs. control 8 ± 8.2 mL, P = 0.005) were observed in control but not in CDCEXO pigs. A two-tailed t-test was used to compare the changes between groups.
Ensite Navx, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ensite navx/product/Abbott Laboratories
Average 90 stars, based on 1 article reviews
ensite navx - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
pentaray catheter  (Biosense Webster)
90
Biosense Webster pentaray catheter
Experimental protocol and delivery technique. (A) Myocardial infarction was induced by 90 min balloon occlusion of the proximal anterior descending branch of the left coronary artery followed by 8 weeks of reperfusion. Cardiac function and scar size were examined by magnetic resonance imaging. Arrhythmia inducibility was probed by programmed electrical stimulation at the left ventricular scar border. If no sustained arrhythmia was induced, programmed electrical stimulation was repeated at the right ventricular apex. High-density three-dimensional <t>electroanatomic</t> mapping was then performed (Rhythmia®, Boston Scientific). Inducible animals were randomly assigned to receive focal injections of either 7.5 mg of CDCEXO in 2 mL of IMDM or 2 mL of IMDM alone. Injections were performed in areas where late potentials were identified using electroanatomical mapping and confirmed by point-by-point mapping (NOGA®, Biosense Webster). Magnetic resonance imaging, electroanatomical mapping, and programmed electrical stimulation were repeated 2 weeks later. Animals were then euthanized, and the heart was removed for histologic and proteomic analysis. (B: Left) High-definition electroanatomical mapping image of the arrhythmogenic substrate with an identified late potential. (Centre) Schematic representation of delivery technique using intracardiac injection catheter (Myostar®, Biosense Webster). (Right) Representative NOGA® map with injection sites (black dots). (C) Animals injected with vehicle alone showed diminished contractile function (CDCEXO 3.11 ± 3.75% vs. control −4.7 ± 4.04%, P = 0.0006). (D) Cardiac output increased in CDCEXO pigs (CDCEXO 278.1 ± 414 mL/min vs. control −586 ± 605 mL/min, P = 0.0027). (E) Deleterious changes in end-systolic volumes (CDCEXO −1.4 ± 3.3 mL vs. control 8 ± 8.2 mL, P = 0.005) were observed in control but not in CDCEXO pigs. A two-tailed t-test was used to compare the changes between groups.
Pentaray Catheter, supplied by Biosense Webster, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pentaray catheter/product/Biosense Webster
Average 90 stars, based on 1 article reviews
pentaray catheter - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
high-density three-dimensional electroanatomic mapping system rhythmia  (Boston Scientific Corporation)
90
Boston Scientific Corporation high-density three-dimensional electroanatomic mapping system rhythmia
Experimental protocol and delivery technique. (A) Myocardial infarction was induced by 90 min balloon occlusion of the proximal anterior descending branch of the left coronary artery followed by 8 weeks of reperfusion. Cardiac function and scar size were examined by magnetic resonance imaging. Arrhythmia inducibility was probed by programmed electrical stimulation at the left ventricular scar border. If no sustained arrhythmia was induced, programmed electrical stimulation was repeated at the right ventricular apex. High-density three-dimensional <t>electroanatomic</t> mapping was then performed (Rhythmia®, Boston Scientific). Inducible animals were randomly assigned to receive focal injections of either 7.5 mg of CDCEXO in 2 mL of IMDM or 2 mL of IMDM alone. Injections were performed in areas where late potentials were identified using electroanatomical mapping and confirmed by point-by-point mapping (NOGA®, Biosense Webster). Magnetic resonance imaging, electroanatomical mapping, and programmed electrical stimulation were repeated 2 weeks later. Animals were then euthanized, and the heart was removed for histologic and proteomic analysis. (B: Left) High-definition electroanatomical mapping image of the arrhythmogenic substrate with an identified late potential. (Centre) Schematic representation of delivery technique using intracardiac injection catheter (Myostar®, Biosense Webster). (Right) Representative NOGA® map with injection sites (black dots). (C) Animals injected with vehicle alone showed diminished contractile function (CDCEXO 3.11 ± 3.75% vs. control −4.7 ± 4.04%, P = 0.0006). (D) Cardiac output increased in CDCEXO pigs (CDCEXO 278.1 ± 414 mL/min vs. control −586 ± 605 mL/min, P = 0.0027). (E) Deleterious changes in end-systolic volumes (CDCEXO −1.4 ± 3.3 mL vs. control 8 ± 8.2 mL, P = 0.005) were observed in control but not in CDCEXO pigs. A two-tailed t-test was used to compare the changes between groups.
High Density Three Dimensional Electroanatomic Mapping System Rhythmia, supplied by Boston Scientific Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/high-density three-dimensional electroanatomic mapping system rhythmia/product/Boston Scientific Corporation
Average 90 stars, based on 1 article reviews
high-density three-dimensional electroanatomic mapping system rhythmia - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Experimental protocol and delivery technique. (A) Myocardial infarction was induced by 90 min balloon occlusion of the proximal anterior descending branch of the left coronary artery followed by 8 weeks of reperfusion. Cardiac function and scar size were examined by magnetic resonance imaging. Arrhythmia inducibility was probed by programmed electrical stimulation at the left ventricular scar border. If no sustained arrhythmia was induced, programmed electrical stimulation was repeated at the right ventricular apex. High-density three-dimensional electroanatomic mapping was then performed (Rhythmia®, Boston Scientific). Inducible animals were randomly assigned to receive focal injections of either 7.5 mg of CDCEXO in 2 mL of IMDM or 2 mL of IMDM alone. Injections were performed in areas where late potentials were identified using electroanatomical mapping and confirmed by point-by-point mapping (NOGA®, Biosense Webster). Magnetic resonance imaging, electroanatomical mapping, and programmed electrical stimulation were repeated 2 weeks later. Animals were then euthanized, and the heart was removed for histologic and proteomic analysis. (B: Left) High-definition electroanatomical mapping image of the arrhythmogenic substrate with an identified late potential. (Centre) Schematic representation of delivery technique using intracardiac injection catheter (Myostar®, Biosense Webster). (Right) Representative NOGA® map with injection sites (black dots). (C) Animals injected with vehicle alone showed diminished contractile function (CDCEXO 3.11 ± 3.75% vs. control −4.7 ± 4.04%, P = 0.0006). (D) Cardiac output increased in CDCEXO pigs (CDCEXO 278.1 ± 414 mL/min vs. control −586 ± 605 mL/min, P = 0.0027). (E) Deleterious changes in end-systolic volumes (CDCEXO −1.4 ± 3.3 mL vs. control 8 ± 8.2 mL, P = 0.005) were observed in control but not in CDCEXO pigs. A two-tailed t-test was used to compare the changes between groups.

Journal: European Heart Journal

Article Title: Biological substrate modification suppresses ventricular arrhythmias in a porcine model of chronic ischaemic cardiomyopathy

doi: 10.1093/eurheartj/ehac042

Figure Lengend Snippet: Experimental protocol and delivery technique. (A) Myocardial infarction was induced by 90 min balloon occlusion of the proximal anterior descending branch of the left coronary artery followed by 8 weeks of reperfusion. Cardiac function and scar size were examined by magnetic resonance imaging. Arrhythmia inducibility was probed by programmed electrical stimulation at the left ventricular scar border. If no sustained arrhythmia was induced, programmed electrical stimulation was repeated at the right ventricular apex. High-density three-dimensional electroanatomic mapping was then performed (Rhythmia®, Boston Scientific). Inducible animals were randomly assigned to receive focal injections of either 7.5 mg of CDCEXO in 2 mL of IMDM or 2 mL of IMDM alone. Injections were performed in areas where late potentials were identified using electroanatomical mapping and confirmed by point-by-point mapping (NOGA®, Biosense Webster). Magnetic resonance imaging, electroanatomical mapping, and programmed electrical stimulation were repeated 2 weeks later. Animals were then euthanized, and the heart was removed for histologic and proteomic analysis. (B: Left) High-definition electroanatomical mapping image of the arrhythmogenic substrate with an identified late potential. (Centre) Schematic representation of delivery technique using intracardiac injection catheter (Myostar®, Biosense Webster). (Right) Representative NOGA® map with injection sites (black dots). (C) Animals injected with vehicle alone showed diminished contractile function (CDCEXO 3.11 ± 3.75% vs. control −4.7 ± 4.04%, P = 0.0006). (D) Cardiac output increased in CDCEXO pigs (CDCEXO 278.1 ± 414 mL/min vs. control −586 ± 605 mL/min, P = 0.0027). (E) Deleterious changes in end-systolic volumes (CDCEXO −1.4 ± 3.3 mL vs. control 8 ± 8.2 mL, P = 0.005) were observed in control but not in CDCEXO pigs. A two-tailed t-test was used to compare the changes between groups.

Article Snippet: High-density three-dimensional electroanatomic mapping was then performed (Rhythmia ® , Boston Scientific).

Techniques: Magnetic Resonance Imaging, Injection, Control, Two Tailed Test